About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of si ...

Atossa Therapeutics, Inc. (ATOS) recently announced promising safety and efficacy data from the company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.(Z)-endoxifen is being assessed as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer as part of the EVANGELINE research.More on the EVANGELINE StudyIn Phase 2 EVANGELINE study, participants are likely to recei ...

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company's leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharma ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage b ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION | --- | --- | |--------------------------------------------------------------|------------------------------------------------------------------------------| | Commission File \nATOSSA (Exact name of registrant | Number: 001-35610 \nTHERAPEUTICS, INC. specified in its charter) | | Delaware | 26-4753208 | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | --- | --- | --- | --- | | ...

Exhibit 99.1 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update • Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024 • First patient dosed in new Phase 2 breast cancer prevention study • Data from ongoing Phase 2 EVANGELINE study scheduled to be presented at 2024 AACR Annual Meeting • Ended 2023 with $88.5 million of cash and cash equivalents and no debt SEATTLE, April 1, 2024— Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...